A broad spectrum of tumour-specific (e.g. mutated KRAS and P53) and tumour-associated (e.g. CA 19-9) markers have the potential to distinguish high- from low-risk lesions and guide decision-making (Table 2) [10•]. This evidence concerns the gene KRAS and neoplasm.